Funding grows for Serentis

MVM Life Science Partners, Apposite Capital and Novo co-led an initial £10.3m first round of funding in the company in July 2007. US venture firm East Hill, which became a shareholder in Serentis following the acquisition of Surface Therapeutics in 2007, also participated in the financing.

Serentis is developing a pipeline of products for the treatment of various dermatological conditions.

“Since our initial financing a year ago, Serentis has made significant progress in identifying and developing our pipeline,” says Serentis CEO and co-founder Tim Sharpington.

“These funds will enable us to move our lead products towards key clinical milestones and to identify additional targets.”

Picture source

Share this story

Close
Menu
Send this to a friend